3.1 Process for Receiving Results and Additional Imaging

3.1 Process for Receiving Results and Additional Imaging

The ARRT Mammography content specifications that took effect September 1, 2025 added patient education about the process for receiving results. That addition is not a customer-service extra. Mammography is the only routine imaging examination with a federal statute — the Mammography Quality Standards Act (MQSA) — that tells a facility what must go to the patient, in what language, and by when. On this exam you are tested on the process, the two different written products, the federal clocks in 21 CFR 900.12, and how a callback differs from a technical repeat. You are not tested on delivering a cancer diagnosis.

Two documents, two audiences

Every complete mammography examination produces two written products, and mixing them is a classic exam trap.

The lay summary (patient letter, “lay letter”) goes to the patient. Under 21 CFR 900.12(c)(2), the facility must provide a summary of the mammography report written in lay terms — words a patient can easily understand. Current FDA implementing guidance for the 2023 MQSA amendments (enforced beginning September 10, 2024) expects that summary to include, at minimum, the patient’s name; the name, address, and telephone number of the facility; an overall assessment of findings; an overall assessment of breast density plus the matching federal density statement; and any recommendations made to the healthcare provider.

The mammography report goes to the referring healthcare provider, or to a provider the patient names. It is the full interpretive record: clinical indication, comparison with prior examinations, findings, overall assessment (the BI-RADS category in ordinary practice), density category, and recommendations. It is not written in the same voice as the lay letter. A patient who opens a portal and reads radiology jargon is not looking at the MQSA lay summary unless the facility designed the portal message to be that summary.

If the patient has no named healthcare provider, MQSA still requires the lay summary and a copy of the technical report, on the same clocks. The facility must also keep a system to refer that patient to a provider when the assessment is probably benign, suspicious, or highly suggestive of malignancy. Self-referred screening is allowed; abandoning the patient after a suspicious read is not.

How patients actually receive results

FDA’s patient-facing MQSA FAQ lists three acceptable ways to deliver the written summary: hand it to the patient at the visit (common when a diagnostic clinic gives a same-day read), provide it electronically (patient portal or electronic chart access), or mail it.

Telephone contact is still part of real workflow. Many facilities call about callbacks, and many radiologists or nurses call when the assessment is suspicious. A phone call is extra communication. It does not replace the written lay summary. Telling a patient “your doctor will call you” does not satisfy 21 CFR 900.12(c)(2). Teach the process in plain language: you will receive a written notice you can understand; it may also appear in your chart; a phone call, if it happens, is in addition to that notice — not instead of it.

Federal clocks — cite the regulation, not a rumor

Do not memorize a made-up “results within three days” federal rule. Current FDA MQSA text in 21 CFR 900.12 uses these clocks:

The 7-day clocks start at final interpretation, not at check-in. A screening study batch-read the next morning has a different start than a diagnostic study interpreted before the patient leaves. Facilities that give verbal results still must hit the written deadlines.

Incomplete assessments that need prior mammograms for comparison also belong in this chapter. The facility still owes a follow-up report with a final overall assessment within 30 calendar days of the initial report, whether or not the priors arrived. Asking the patient to help locate old films is results communication, not a positioning trick.

Breast density is now a federal results requirement

Image Production covers how density is classified on the report. This chapter covers the patient-facing piece, which the 2023 MQSA amendments made a nationwide requirement as of September 10, 2024, independent of older state density laws.

The interpreting physician assigns one of four overall density statements on the report (almost entirely fatty; scattered areas of fibroglandular density; heterogeneously dense, which may obscure small masses; extremely dense, which lowers the sensitivity of mammography). For the lay letter, FDA collapses those four into two patient messages (21 CFR 900.12(c)(2)(iii) and (iv)):

• Not dense (fatty or scattered): tissue can be dense or not dense; dense tissue makes cancer harder to find on a mammogram and raises the risk of developing breast cancer; your breast tissue is not dense; talk with your healthcare provider about density, risk, and your situation.
• Dense (heterogeneously or extremely dense): the same opening, then your breast tissue is dense; in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers; talk with your healthcare provider.

You do not pick the category at the gantry. You do need to explain why the letter mentions density and who discusses supplemental screening. A density question at checkout is a results-communication question. It is not an invitation to quote a BI-RADS number or to order ultrasound on your own authority.

The mammographer’s lane versus the clinician’s lane

The mammographer explains the process: when the written notice should arrive, that a portal screenshot may not be the lay letter, how to request images, what a callback appointment involves (extra time, possible ultrasound, possible wait for a radiologist), and that additional pictures do not by themselves mean cancer. The interpreting physician or referring clinician explains the findings: what this patient’s density statement means, why a diagnostic mammogram is recommended, and what the assessment category implies for follow-up.

If a patient asks “Do I have cancer?” after screening, redirect without inventing an interpretation. You can say that screening results come in writing, that a return visit for extra images is common, and that the radiologist or her provider will discuss findings. Offering a hallway opinion from what you saw on the acquisition monitor can contradict the final report and exceeds your role.

Reasons for additional imaging — do not mix the terms

Technical repeat. The images fail quality standards: motion unsharpness, inadequate compression, poor pectoralis visualization on the mediolateral oblique (MLO) view, a skin fold that hides tissue, a detector or grid artifact, or an exposure problem. The patient may wait or return the same day. This is an image-quality event. Document the reason. Do not describe it as “the doctor saw something.”

Callback / recall. A screening examination interpreted as incomplete (BI-RADS 0) because a finding needs additional imaging or because comparison with prior mammograms is needed. The patient returns for diagnostic mammography, ultrasound, or both. Most callbacks are not cancer. Screening views are standardized; they are not problem-solving views. Explaining that distinction is exactly the “process for receiving results and additional imaging” the 2025 blueprint added.

Diagnostic workup. The examination is scheduled as diagnostic from the start because of a clinical problem (lump, discharge, skin change) or because screening already identified a finding that needs extra views. Diagnostic mammography uses additional projections, spot compression, magnification, and often targeted ultrasound. Documentation, time stamps, and often same-day results conversations all differ from screening.

When you schedule additional imaging, tell the patient what will happen and that written MQSA results still apply. That is patient education. Interpreting the new images is not.